RBC Capital Maintains Outperform on Revolution Medicines, Raises Price Target to $203

Revolution Medicines

Revolution Medicines

RVMD

0.00

RBC Capital analyst Leonid Timashev maintains Revolution Medicines (NASDAQ: RVMD) with a Outperform and raises the price target from $182 to $203.